Anthony Iacovone | Source | BioSymetrics Inc.
Anthony Iacovone
Anthony Iacovone has been at the forefront of the artificial intelligence and machine learning technology applied to the marketing and biomedical industries for the past 20 years. Having spent the bulk of his career working to innovate and improve the AI ecosystem, he’s passionately invested in the continued development of a model in which artificial intelligence can be applied to help improve outcomes across various industries.
-
BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19 | BioSymetrics | Drug Discovery Accelerated
Janssen Pharmaceuticals and Sema4 partnership announcement on projects using BioSymetrics Contingent AI platform
Article -
The Business of Healthcare Podcast, Episode 48: Artificial Intelligence and Machine Learning for Healthcare
Anthony Iacovone, Chairman of BioSymetrics, joins host Dr. Bob Kaiser for a discussion about what biomedical artificial intelligence and machine learning are and how they can be used to improve outcomes in the areas of drug discovery, clinical diagnostics and value-based care as well as reduce healthcare costs.
Podcast -
BioSymetrics Joins Accenture’s INTIENT Network
"BioSymetrics’ participation in the ecosystem and integration with Accenture's INTIENT network will give scientists another important capability to help interpret the growing volumes of rich and diverse data that is being generated in drug discovery.”
Article
-
“Although we’ve been working on deploying AI in the clinical setting for several years, demonstrating that machine learning can bring speed and precision to helping identify at risk patient populations, predict disease outcomes, and build better treatments, it has been the COVID pandemic has now pushed biomedical AI technology to the fore front of innovative necessity.”
